Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

Background: In IPASS (NCT00322452), progression-free survival (PFS, primary endpoint) was significantly longer with first-line gefitinib versus carboplatin/paclitaxel in never/light ex-smokers with advanced pulmonary adenocarcinoma in Asia, both in the overall intent-to-treat (ITT) population and in...

Saved in:

書目詳細資料
Main Authors:	Wu Y.-L., Fukuoka M., Mok T.S.K., Saijo N., Thongprasert S., Yang J.C.H., Chu D.-T., Yang J.-J., Rukazenkov Y.
格式:	Article
語言:	English
出版:	2014
在線閱讀:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84879884557&partnerID=40&md5=6d90e1b7010d2dea5e5624bd15e89ef8 http://www.ncbi.nlm.nih.gov/pubmed/23540718 http://cmuir.cmu.ac.th/handle/6653943832/4048
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Wu Y., et al.
出版: (2017)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Fukuoka M., et al.
出版: (2017)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Masahiro Fukuoka, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
由: Thongprasert S., et al.
出版: (2014)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
由: Sumitra Thongprasert, et al.
出版: (2018)

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
由: Thongprasert,S., et al.
出版: (2015)

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
由: Thongprasert S., et al.
出版: (2014)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
由: Wong, A.S., et al.
出版: (2014)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Lee C., et al.
出版: (2017)

Lung cancer working group report
由: Saijo N., et al.
出版: (2017)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
由: Sudo, M., et al.
出版: (2014)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
由: Afrita Amalia Laitupa, -, et al.
出版: (2019)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
由: Wong, A.S., et al.
出版: (2014)

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
由: De Lima Lopes Jr., G., et al.
出版: (2016)

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
由: Mok T., et al.
出版: (2017)

Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer
由: Zee, Y.-K., et al.
出版: (2014)

Short-hairpin RNA library: Identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
由: Sudo M., et al.
出版: (2020)

Lung cancer working group report
由: Nagahiro Saijo, et al.
出版: (2018)

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
由: James Chih Hsin Yang, et al.
出版: (2018)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
由: Mark Boye, et al.
出版: (2018)

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
由: Cho B.C.
出版: (2023)

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
由: Tony Mok, et al.
出版: (2018)

Analysis of the four combination chemotherapies in non-small cell lung cancer treated at Maharaj Nakorn Chiang Mai Hospital
由: Thongprasert S.
出版: (2014)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
由: Assiddiq, B.F., et al.
出版: (2014)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
由: Ku, G.Y., et al.
出版: (2016)

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
由: Nokihara, H, et al.
出版: (2022)

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry
由: Wang, L.-Z., et al.
出版: (2014)

SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
由: Auliya Hafizah, Raysa

Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year
由: Charoentum C.
出版: (2014)

Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year
由: Chaiyut Charoentum
出版: (2018)

Combination of tumor fragments and nanotechnology as a therapeutic approach: Treating a tumor with tumor
由: Chen, X, et al.
出版: (2022)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
由: Wang D.D., et al.
出版: (2019)